I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
At-Risk for Type 1 Diabetes Extension Study
This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …
type 1 diabetes mellitus
diabetes
teplizumab
- 0 views
- 19 Feb, 2024